595. Deputy Ken O'Flynn asked the Minister for Health whether her Department has examined the approach in other EU countries with universal health systems in relation to pursuing unpaid hospital charges; and to indicate whether reforms are under consideration to reduce reliance on private debt collectors. [53098/25]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn .
3,835 questions match, newest first.
596. Deputy Ken O'Flynn asked the Minister for Health whether her Department intends to publish an annual report detailing hospital debts, recovery rates and payments made to collection firms, in the interests of transparency and public accountability. [53099/25]
597. Deputy Ken O'Flynn asked the Minister for Health if her Department has assessed the implications for public health of requiring people to work into their late sixties, in particular regarding occupational health and chronic illness and if she will publish those assessments. [53106/25]
609. Deputy Ken O'Flynn asked the Minister for Health if she will designate a liaison officer within the HSE to support survivors of industrial and reformatory schools in accessing community health and social care services; and if she will make a statement on the matter. [53214/25]
652. Deputy Ken O'Flynn asked the Minister for Health if her Department has carried out an assessment of the cumulative impact of recent premium increases by private health insurers on families and older persons; and if she will publish that assessment. [53423/25]
653. Deputy Ken O'Flynn asked the Minister for Health the engagement her Department has had with the Health Insurance Authority regarding multiple premium increases in 2025; and whether measures are being considered to improve affordability for policyholders. [53424/25]
654. Deputy Ken O'Flynn asked the Minister for Health the estimated number of policyholders who will face annual health insurance premium increases of more than €500 following the most recent changes by providers (details supplied); and if she will provide a breakdown by insurer. [53425/25]
655. Deputy Ken O'Flynn asked the Minister for Health if she will report on the trend in voluntary health insurance coverage rates since 2020; and whether recent increases in premiums risk reducing coverage among middle-income households. [53426/25]
656. Deputy Ken O'Flynn asked the Minister for Health the measures being examined by her Department to protect consumers from unexpected or multiple premium hikes within a single year; and if she will consider requiring insurers to provide advance notice and transparent justification of such increases. [53427/25]
657. Deputy Ken O'Flynn asked the Minister for Health if she has examined the extent to which rising private health insurance costs are leading to increased pressure on the public hospital system; and if her Department has commissioned any modelling in this regard. [53428/25]
658. Deputy Ken O'Flynn asked the Minister for Health if she will outline the engagement her Department has had with the Department of Finance regarding taxation treatment of health insurance reliefs in the context of rising premiums; and whether any changes are being considered to maintain affordability. [53429/25]
659. Deputy Ken O'Flynn asked the Minister for Health if she has met with representatives of providers (details supplied) in 2025 to discuss premium increases; if so, on what dates; and if she will publish the minutes of those meetings. [53430/25]
452. Deputy Ken O'Flynn asked the Minister for Health the number of oncology drugs approved for use by the European Medicines Agency in each of the years 2020 to 2025; and to specify which of these are currently reimbursed under the public health system, which are only available privately, and the average waiting time from EMA approval to HSE reimbursement. [52823/25]
453. Deputy Ken O'Flynn asked the Minister for Health whether there are cancer drugs currently accessible to private patients in Ireland which are not reimbursed for public patients; and the steps being taken to eliminate this disparity in access. [52824/25]
454. Deputy Ken O'Flynn asked the Minister for Health the average time taken by the National Centre for Pharmacoeconomics and her Department to complete health technology assessments and reimbursement decisions on oncology drugs in the past three years; and whether target timelines exist to expedite access for public patients. [52825/25]
455. Deputy Ken O'Flynn asked the Minister for Health if her Department has entered into outcomes-based or risk-sharing agreements with pharmaceutical companies in respect of new cancer drugs; and if so, to provide details of the drugs concerned, the duration of the agreements, and the outcomes being measured. [52826/25]
456. Deputy Ken O'Flynn asked the Minister for Health the projected level of additional annual funding required over the next five years to ensure that all newly approved cancer drugs are made available to public patients in a timely manner; and whether ring-fenced oncology funding is being considered within her Department. [52827/25]
457. Deputy Ken O'Flynn asked the Minister for Health whether her Department has carried out any equality or impact assessment on disparities in access to oncology drugs between public and private patients; and if so, to publish those findings. [52828/25]
458. Deputy Ken O'Flynn asked the Minister for Health to provide comparative data on the time from European Medicines Agency approval to reimbursement for new oncology medicines in Ireland versus other EU member states; and to indicate whether Ireland is above or below the EU average. [52829/25]
459. Deputy Ken O'Flynn asked the Minister for Health if she will publish in full the rationale, minutes, and assessments underpinning reimbursement decisions on oncology drugs since 2020; and if not, the reason for the continued confidentiality. [52830/25]
460. Deputy Ken O'Flynn asked the Minister for Health whether a national registry of oncology patients treated with newer cancer therapies is maintained; and if so, to outline how this real-world data informs reimbursement and future access decisions. [52831/25]
461. Deputy Ken O'Flynn asked the Minister for Health the steps being taken to accelerate the availability of oncology generics and biosimilars to reduce cost barriers for the public health system; and whether legislative or regulatory reform is being considered in this regard. [52832/25]
190. Deputy Ken O'Flynn asked the Minister for Health if she will direct the HSE to provide a full explanation of the scientific and clinical rationale for including the phrase “anyone who identifies as a woman” in its information on menopause, given that menopause is a biological process experienced by females. [52370/25]
191. Deputy Ken O'Flynn asked the Minister for Health if she will instruct the HSE to release details of the peer-review process for its menopause guidance, including the names and qualifications of medical experts consulted, and to provide this information directly to Members of the Oireachtas. [52371/25]
192. Deputy Ken O'Flynn asked the Minister for Health whether she accepts responsibility for ensuring the accuracy of all information issued by the HSE on menopause; and if she will direct the HSE to remove any language that does not reflect established biological and medical science. [52372/25]